[{"id":"469567bc-6e2c-486a-ac36-30c6f9bfeddd","acronym":"TQ-B3101-II-02","url":"https://clinicaltrials.gov/study/NCT04306887","created_at":"2021-01-18T20:53:05.880Z","updated_at":"2024-07-02T16:36:48.658Z","phase":"Phase 2","brief_title":"A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)","source_id_and_acronym":"NCT04306887 - TQ-B3101-II-02","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anboni (unecritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/29/2019","start_date":" 11/29/2019","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2020-03-13"},{"id":"06d347bd-fe68-4c6c-8d21-ad1360754268","acronym":"","url":"https://clinicaltrials.gov/study/NCT03972189","created_at":"2021-01-18T19:32:26.325Z","updated_at":"2024-07-02T16:36:56.872Z","phase":"Phase 2","brief_title":"Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03972189","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 positive","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anboni (unecritinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 111","initiation":"Initiation: 07/24/2019","start_date":" 07/24/2019","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2019-08-15"}]